Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Demonstrate the efficacy of Dronedarone in preventing major cardiovascular events
(stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or
unplanned cardiovascular hospitalization or death from any cause in patients with
permanent Atrial Fibrillation [AF] and additional risk factors
Secondary Objective:
- Demonstrate the efficacy of Dronedarone in preventing cardiovascular death
This was an event-driven study where a common study end date [CSED] was to be determined by
Steering Committee based on the number of events (stroke, systemic arterial embolism,
myocardial infarction or cardiovascular death).